Latest News
& Press Releases

AstraZeneca announced that it will voluntarily pull Vaxzevria from the global market amid a sharp decline in demand and following the company’s recent admission that its vaccine is linked with a rare side effect.

As interest in psychedelic therapies ramp up, Lykos Therapeutics will go in front of the FDA’s Psychopharmacologic Drugs Advisory Committee on June 4 to present its investigational treatment for post-traumatic stress disorder.

Pfizer’s investigational Duchenne muscular dystrophy gene therapy fordadistrogene movaparvovec has been hit with another patient death, forcing the pharma to pause dosing in its Phase III study.

As Sarepta Therapeutics moves closer to full approval and an expanded label for its gene therapy, some experts push back on clinical efficacy and cost while others note the hope it provides patients with Duchenne muscular dystrophy.

The biotech touted its prime editing technology at ASGCT on Tuesday after receiving FDA clearance last week for a clinical study of a drug candidate based on the platform.

Tuesday afternoon’s session was standing room only as representatives from various biopharma companies presented on their work to improve the efficiency and quality of AAV production.

AAVs and accelerated approval are just two of the topics being discussed at ASGCT. Meanwhile, the race between Vertex and bluebird bio’s gene therapies Casgevy and Lyfgenia is heating up.

With appeals and additional cases still pending, it remains to be seen if any of the arguments being brought by biopharma companies against the U.S. government will hold up in court.

The FDA is looking at four decision deadlines in the coming three weeks, including two for a CAR-T therapy and another for a hepatitis B vaccine.

The newest company by the life sciences venture capital firm, Prologue Medicines will search through the vast viral proteome to identify proteins with therapeutic potential.

With a total revenue of nearly $2.7 billion, Vertex exceeded analyst estimates in the first quarter, bolstered by strong uptake of its cystic fibrosis products.

ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory marginal zone lymphoma.

The company highlights the critical role of unified digital platforms in ensuring compliance, sponsor trust, and clinical readiness.

Highlights ● Insilico published a new study unveiling Target Identification Pro (TargetPro), a superior disease-specific model, and TargetBench 1.0, the first standardized benchmarking framework for target discovery. ● TargetPro achieved 71.6% retrieval of known clinical targets, a 2–3x improvement over large language models (LLMs) such as GPT-4o, Grok3, DeepSeek-R1, Claude-Opus-4, BioGPT, and public platforms like Open Targets. ● TargetPro’s predicted novel targets demonstrated 95.7% structure availability, 86.5% druggability, and 46% repurposing potential, outperforming competing systems on all measures. ● TargetBench’s explainable AI models revealed disease-specific feature importance patterns, emphasizing the value of disease-specific target identification models. ● New gold standard approaches improve accuracy, reliability, and transparency in AI-driven drug discovery.